AB0626 Dynamic study of B-cells using highly sensitive flow cytometry (HSFC) in systemic lupus erythematosus patients' receiving anti-B-cell therapy. (23rd January 2014)

• Record Type: Journal Article
• Authors: Tsanyan, M.E.; Aleksankin, A.; Aleksandrova, E.N.; Soloviev, S.K.; Nasonov, E.L.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 674
• Page End: 674
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.626
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: Dynamic study of B-cell using HSFC in systemic lupus erythematosus (SLE) patients'(pts) receiving anti-B-cell therapy with Rituximab (RTM) and definition of correlation with clinical and laboratory disease activity on the background of the therapy. Methods: 41 pts with definite SLE (7 male, 35 female; mean age Me 28 [23-40]) were included. 19 of them received a second course of RTM. 41pts were examined before treatment and after 1 month, 13 and 11 of them after 3 and 6 months respectively. SLE activity was assessed with SLEDAI2K scale. B lymphocytes number was evaluated using HSFC on BECKMAN COULTER CYTOMICS FC 500 (USA). Minimum detectable concentration of CD3-CD19+ was 1O10 3 cells/μl. 3pts received RTM in a total dose of 2000mg, 34pts 1000mg, 4pts 500 mg. Anti-double-stranded DNA (anti-ds-DNA) was assessed using immunoenzyme methods. Results: Before treatment B-cells was reduced in 25pts (El0, 967 [0.17-2.45]%), compared to the other 16pts (El14.61 [9.43-19.37]%). At 1 month after therapy 25pts with reduced B-cell numbers exhibited complete depletion (El0[0-0.1]%, p=0.0002) and SLEDAI2K had lower values (Me 8 [4-14]) than in 16pts with incomplete depletion (El0.2665 [0.05-0.66]%, d=0.0004) with higher SLEDAI2K score (Me 10 [6-20]). In the group of pts (n=3) receiving RTM in a total dose of 2000mg, 2pts had reduced number of B-cells but in 1pt number of B-cells was normal. At 1 month after RTM treatment all has developed a complete depletion. In the group of pts (n=4) receiving RTM in a total dose of 500mg, number of B-cells was also reduced. At 1month after treatment 3 of this pts exhibited complete depletion but in 1pt number of B-cells did not change and at 1 week after the infusion had developed rashes on the hands (delayed allergic reaction). In the group of pts (n=34) receiving RTM in a total dose of 1000mg, number of B-cells were also reduced El3, 67[0, 6-12, 89]%. In this group, at 1 month after therapy pts exhibited incomplete depletion El0, 07 [0-0, 333]%, d=0. Correlation analysis of B cells and SLE activity showed a significant association between the number of B-cells, the level of anti-ds-DNA and the SLEDAI2K index before treatment and after 1, 3, 6 months. Number of B cells also correlated with the level of C3, C4 components of complement before therapy and with the C3 component at 1 month after therapy. Found no correlation between levels of C3, C4 and B-cells at 3, 6 months after therapy RTM. Conclusions: The number CD3-CD19+ lymphocytes was associated with clinical and laboratory activity of SLE: SLEDAI2K, anti-ds-DNA. After treatment reduction in the number of B-lymphocytes correlates with decreased levels of anti-ds-DNA and the index SLEDAI2K through 1, 3, 6 months after therapy RTM. Found no correlation of B cells and C3, C4 complement components. Disclosure of Interest: None Declared